Platelet Derived Growth Factor Receptor (PDGFR) Inhibitor Crenolanib in Children and Young Adults With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Recurrent High-Grade Glioma Including Diffuse Intrinsic Pontine Glioma.

Trial Profile

Platelet Derived Growth Factor Receptor (PDGFR) Inhibitor Crenolanib in Children and Young Adults With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Recurrent High-Grade Glioma Including Diffuse Intrinsic Pontine Glioma.

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs Crenolanib (Primary)
  • Indications Glioma
  • Focus Adverse reactions; Biomarker; Pharmacogenomic; Pharmacokinetics
  • Most Recent Events

    • 31 Oct 2016 Status changed from active, no longer recruiting to completed.
    • 21 Oct 2015 Planned End Date changed from 1 Sep 2015 to 1 Mar 2017 as reported by ClinicalTrials.gov record.
    • 19 May 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Apr 2015 to 1 Sep 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top